biomarker measurement

Cognisci Labs develops CerebralScore, a saliva-based test that analyzes cell-free DNA methylation patterns to map brain-origin fragments and distinguish dementia subtypes. The company sequences millions of DNA fragments from a single saliva sample and compares their methylation signatures to an atlas of 450+ cell types, using regional deconvolution to identify which brain regions are shedding DNA. Analysis is performed in a CLIA-certified lab, and CerebralScore is rolling out to a beta cohort in the U.S.

cfDNA analysisDNA sequencingmethylation analysisregional deconvolution

Definitive Diagnostics develops an AI-enabled, protein-based blood test platform for earlier cancer detection. Its patented method measures 16 abundant protein/immune biomarkers forming cancer-specific patterns, designed to reduce false positives and unnecessary procedures. The company reports independent validation of 99% sensitivity (Stage 0 breast), 97% specificity, and 98% Tissue of Origin, and has detected cancer as early as Stage 0 in breast and Stage I in lung, colorectal, ovarian, and pancreatic cancers.

AI-supported detectionliquid biopsyprotein pattern recognitionTissue of Origin determination

ExOcular is developing a portfolio of blood-based multiplex tests that measure disease-specific biomarkers isolated from exosomes to help manage severe eye diseases, initially focusing on diabetic retinopathy and age-related macular degeneration. Its analysis algorithms generate a quantitative Disease Severity Score to support early diagnosis, prognosis, and treatment monitoring. Headquarters and lab are located at the University of Colorado Anschutz Medical Campus.

analysis algorithms generating Disease Severity Scoreclinical trial enrichmentexosome isolationmultiplex biomarker panelstherapy monitoring